

ANSWERING REVIEWERS

Manuscript NO: 34840

Reviewer's code: 03656572

Reviewer's country: China

COMMENTS TO AUTHORS

In this review, the author provided an overview of the current evidence-based information on HBV reactivation following immunosuppressive treatments for oncohematological tumors. The author emphasized that in case of serological sign(s) of current or past infection with the virus, appropriate therapeutic or preventive strategies are suggested, according to both virological categories, risk of HBVr by immunosuppressive drugs and liver status. Either antiviral drug management and surveillance and pre-emptive approach are examined, commenting the current international recommendations about this debated issue. This review is described in detail, which, as valuable information, could help the readers that have better understand the first-hand knowledge of this topic to start novel studies.

ANSWER

We thank Reviewer#1 for his positive opinion on our paper.

Minor language polishing has been performed.

Reviewer's code: 03476715

Reviewer's country: China

COMMENTS TO AUTHORS

This is a well written paper.

ANSWER

We also thank Reviewer#2 for his positive opinion on our paper.